Saroja Pharma FY26 net profit rises 56.4% to ₹161.80 crore
Saroja Pharma Industries India Limited reported a 56.4% increase in net profit to ₹161.80 crore for FY26, with revenue rising 30.5% to ₹7,012.90 crore. The Board approved the audited results with an unmodified opinion from the statutory auditor. The company also confirmed the full utilization of IPO proceeds totaling ₹911.23 crore.
*this image is generated using AI for illustrative purposes only.
Saroja Pharma Industries India Limited reported a 56.4% increase in net profit to ₹161.80 crore for the financial year ended March 31, 2026, driven by a 30.5% rise in revenue from operations to ₹7,012.90 crore. The company’s Board of Directors approved the audited standalone financial results for the half year and full year on May 30, 2026, following the recommendation of the Audit Committee.
The statutory auditor, Pravin Chandak & Associates, issued an unmodified opinion on the financial results, confirming they are presented in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditor affirmed that the results provide a true and fair view of the company's financial performance in conformity with Indian Accounting Standards.
Financial Performance
Revenue from operations for the year ended March 31, 2026, stood at ₹7,012.90 crore, compared to ₹5,372.68 crore in the previous year. Total income from operations rose to ₹7,023.81 crore. The company managed its total expenses effectively, which increased to ₹6,800.01 crore from ₹5,246.28 crore in the prior year, resulting in a profit before tax of ₹223.79 crore.
The Basic Earning Per Share (EPS) for the year improved to ₹4.02 from ₹2.57 in the previous year. For the half year ended March 31, 2026, the company reported a net profit of ₹104.46 crore on revenue from operations of ₹3,176.92 crore.
| Financial Metric (₹ in Lakhs) | Year Ended 31.03.2026 | Year Ended 31.03.2025 |
|---|---|---|
| Net Sales / Income From Operations | 7,012.90 | 5,372.68 |
| Total Income from Operations (Net) | 7,023.81 | 5,391.20 |
| Total Expenses | 6,800.01 | 5,246.28 |
| Profit before Tax | 223.79 | 144.92 |
| Net Profit | 161.80 | 103.42 |
| Basic Earning Per Share (₹) | 4.02 | 2.57 |
IPO Proceeds Utilization
The company confirmed that it has fully utilized the proceeds from its Initial Public Offer (IPO), which amounted to ₹911.23 crore. The funds were allocated towards setting up a manufacturing unit, repaying unsecured loans, and covering public issue expenses. A certificate confirming the object-wise utilization was issued by the statutory auditor and approved by the Board.
| Object Of the Issue | Amount Allotted For Project | Amount utilized till 31 March 2026 |
|---|---|---|
| To Set - up a Manufacturing Unit | 704.88 | 704.88 |
| To Repay the Unsecured Loan of the Company | 175.00 | 175.00 |
| Public Issue Expenses | 31.35 | 31.35 |
| Total | 911.23 | 911.23 |
The trading window for dealing in the company's securities by insiders will open 48 hours after the declaration of the financial results.
Historical Stock Returns for Saroja Pharma Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | -22.62% | -22.43% | -52.38% |
How will the completion of the new manufacturing unit impact production capacity and revenue growth in the next fiscal year?
What is the company's strategy for managing growth now that the IPO proceeds are fully utilized and unsecured loans are repaid?
Will the reduction in debt leverage lead to improved credit ratings or lower borrowing costs for future expansion?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
